Sign in
Taking people in United StatesNo phase

Registry following adults with chronic hand eczema during routine dermatology care

Collects long-term information on adults with chronic hand eczema and their treatments.

Key facts

Who runs it
CorEvitas
Where
Waltham, United StatesSee the site
Trial code
Registry title
PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry
Status
Recruiting
People taking part
2,000 people, planned
Started
21 Jul 2026
Expected to end
31 Dec 2099
Type of study
Observational
Treatments tested
  • Observational (Non-Interventional) Registry
Record updated
26 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry is looking for adults with moderate-to-severe chronic hand eczema who are starting a registry-listed medication under a dermatologist or other qualified provider.

Age
18 years or older, and old enough to give legal consent where the research takes place.
Sex
All sexes can join.
Disease stage
Moderate-to-severe chronic hand eczema, diagnosed by a dermatologist or other qualified healthcare provider.
Earlier treatment
The person must be starting a medication that the registry accepts at the time of joining.

Main reasons for not taking part

  • Taking part in, or planning to take part in, a blinded clinical trial for a chronic hand eczema drug

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • To be eligible to participate in this registry, an individual must meet all of the following criteria:; Diagnosed with moderate-to-severe CHE by a dermatologist or other qualified healthcare provider at the time of enrollment and initiating an eligible medication; Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment; Is willing and able to consent to participation in the registry; Is willing and able to complete registry-related forms electronically via personal devices; Is willing and able to provide the information (first name, last name, email address, language and primary time zone) required to create an account to allow you to complete registry forms via a personal device; Is willing and able to provide Personal Information (full legal name, sex, date of birth, home address zip or postal code and email address or phone number at a minimum) if required based on registry location and applicable laws and regulations

Who cannot take part

  • Is participating or planning to participate in a blinded clinical trial for a CHE drug
  • An individual who meets any of the following criteria will be excluded from participation in the registry:

Where in United States

  • CorEvitas, LLCWaltham, United StatesContact: Chronic Hand Eczema Registry TeamTaking people

About the trial

What the trial wants to find out

The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualified healthcare provider. Longitudinal data are collected from both subjects and their treating provider during routine clinical encounters using a structured and standardized data collection method

Treatments tested

  • Observational (Non-Interventional) Registry

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry
Plain-language title
Registry following adults with chronic hand eczema during routine dermatology careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 August 2026